Evidence map›Paper›PMID 25907167›Full record

ReviewAnnals of the New York Academy of Sciences2015

Personalized medicine in diabetes mellitus: current opportunities and future prospects.

Jeffrey W Kleinberger, Toni I Pollin

Abstract readReview
In one paragraph

Review in Annals of the New York Academy of Sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. A synonymousMolecular genetics and metabolism reports · 2024
    Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Dementia in Diabetes: The Role of Hypoglycemia.International journal of molecular sciences · 2023
    Review
  15. Article
  16. Research in pharmaceutical sciences · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jeffrey W KleinbergerDivision of Endocrinology, Diabetes, and Nutrition and Program in Personalized and Genomic Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
Toni I PollinDivision of Endocrinology, Diabetes, and Nutrition and Program in Personalized and Genomic Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.

Funding

Research BaseP30DK072488 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI MITCHELL, BRAXTON D, TAYLOR, SIMEON I. · 2005 to 2019
$17.3M
Fine-mapping and Characterization of Metabolic Loci in the DPP Outcomes StudyR01DK072041 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI FLOREZ, JOSE CARLOS · 2005 to 2017
$7.6M
Genomic Diagnosis and Individualized Therapy of Highly Penetrant Genetic Diabetes (Administrative Supplment)U01HG007775 · NHGRI · UNIVERSITY OF MARYLAND BALTIMORE · PI POLLIN, TONI I. · 2014 to 2018
$4.3M
The Metabolic Impact of Congenital Heterozygous ApoC-III Deficiency in HumansR01HL104193 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI POLLIN, TONI I. · 2011 to 2015
$3.0M
Diabetes, Obesity, and Metabolic ComplicationsT32DK098107 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI TAYLOR, SIMEON I. · 2015 to 2025
$2.4M
NHGRI NIH HHS U01 HG007775NHLBI NIH HHS R01 HL104193NIDDK NIH HHS P30 DK072488NIDDK NIH HHS R01 DK072041NIDDK NIH HHS R01 DK72041NIDDK NIH HHS T32 DK098107
6 · The paper itself

Abstract

Diabetes mellitus affects approximately 382 million individuals worldwide and is a leading cause of morbidity and mortality. Over 40 and nearly 80 genetic loci influencing susceptibility to type 1 and type 2 diabetes, respectively, have been identified. In addition, there is emerging evidence that some genetic variants help to predict response to treatment. Other variants confer apparent protection from diabetes or its complications and may lead to development of novel treatment approaches. Currently, there is clear clinical utility to genetic testing to find the at least 1% of diabetic individuals who have monogenic diabetes (e.g., maturity-onset diabetes of the young and KATP channel neonatal diabetes). Diagnosing many of these currently underdiagnosed types of diabetes enables personalized treatment, resulting in improved and less invasive glucose control, better prediction of prognosis, and enhanced familial risk assessment. Efforts to enhance the rate of detection, diagnosis, and personalized treatment of individuals with monogenic diabetes should set the stage for effective clinical translation of current genetic, pharmacogenetic, and pharmacogenomic research of more complex forms of diabetes.

Indexed as

Precision MedicineAdministration, OralDiabetes MellitusDiabetes Mellitus, Type 2Gene-Environment InteractionGenetic TestingHumansHypoglycemic AgentsLife StylePharmacogeneticsHypoglycemic Agentsmonogenic diabetespharmacogenetics, gene-environment interactionpharmacogenomicstype 2 diabetes

Identifiers

PMID25907167
PMCPMC4480162

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.